Enteral Zinc to Improve Growth in Infants at Risk for Bronchopulmonary Dysplasia
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Bronchopulmonary Dysplasia
- Growth Failure
- Infant,Premature
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Infants will be stratified by gestational age (23-24 wks, 25-26 wks, 27-29 wks) and then are randomized to receive supplemental oral zinc acetate or no zinc acetate.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Younger than 28 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03532555
- Collaborators
- Intermountain Research and Medical Foundation
- Investigators
- Principal Investigator: Bradley Yoder, MD University of Utah